Virtus ETF Advisers LLC Fate Therapeutics Inc Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$2.02 - $5.04 $3,654 - $9,117	-1,809 Reduced 9.03%	18,216 $38,000
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $63,974 - $88,569	13,440 Added 204.1%	20,025 $95,000
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $10,718 - $28,111	-2,528 Reduced 27.74%	6,585 $37,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $34,569 - $83,547	3,506 Added 62.53%	9,113 $91,000
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $862 - $1,478	41 Added 0.74%	5,607 $126,000
Q2 2022 Aug 12, 2022	BUY	$17.78 - $42.39 $44,005 - $104,915	2,475 Added 80.07%	5,566 $138,000
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $5,429 - $11,031	-183 Reduced 5.59%	3,091 $120,000
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $43,917 - $59,064	918 Added 38.96%	3,274 $192,000
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $7,705 - $12,444	-130 Reduced 5.23%	2,356 $140,000
Q2 2021 Aug 10, 2021	SELL	$67.25 - $92.52 $41,964 - $57,732	-624 Reduced 20.06%	2,486 $216,000
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $3,535 - $5,752	49 Added 1.6%	3,110 $256,000
Q4 2020 Feb 12, 2021	SELL	$38.09 - $100.95 $265,373 - $703,318	-6,967 Reduced 69.48%	3,061 $278,000
Q3 2020 Nov 13, 2020	SELL	$30.41 - $40.5 $41,388 - $55,120	-1,361 Reduced 11.95%	10,028 $401,000
Q2 2020 Aug 05, 2020	SELL	$20.21 - $35.23 $156,546 - $272,891	-7,746 Reduced 40.48%	11,389 $391,000
Q1 2020 May 14, 2020	SELL	$17.28 - $31.88 $48,072 - $88,690	-2,782 Reduced 12.69%	19,135 $425,000
Q4 2019 Feb 13, 2020	BUY	$13.39 - $20.73 $103,651 - $160,470	7,741 Added 54.61%	21,917 $429,000
Q3 2019 Nov 12, 2019	SELL	$15.47 - $22.5 $12,205 - $17,752	-789 Reduced 5.27%	14,176 $220,000
Q2 2019 Aug 13, 2019	SELL	$15.61 - $20.44 $25,709 - $33,664	-1,647 Reduced 9.91%	14,965 $304,000
Q1 2019 May 14, 2019	SELL	$13.15 - $18.71 $22,723 - $32,330	-1,728 Reduced 9.42%	16,612 $292,000
Q4 2018 Feb 05, 2019	SELL	$11.48 - $16.98 $226,775 - $335,422	-19,754 Reduced 51.86%	18,340 $235,000
Q3 2018 Nov 14, 2018	SELL	$8.75 - $16.29 $244,816 - $455,777	-27,979 Reduced 42.35%	38,094 $621,000
Q2 2018 Aug 10, 2018	BUY	$9.16 - $13.48 $605,228 - $890,664	66,073 New	66,073 $749,000

Others Institutions Holding FATE

# of Institutions

177

Shares Held

113M

Call Options Held

53.7K

Put Options Held

Redmile Group, LLC San Francisco, CA

13.2M
Shares

$18.7 Million
3.01% of portfolio
Vanguard Group Inc Valley Forge, PA

10.4M
Shares

$14.8 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$14.4 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

5.57M
Shares

$7.91 Million
0.72% of portfolio
State Street Corp Boston, MA

5.25M
Shares

$7.46 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $138M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account